"id","uuid:ID","description","rationale","instanceType","name","label"
"StudyDesign_1","8057e508-5305-41ae-a993-75a19bdb8503","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","Study Design 1",""
